for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cambrex Corporation

CBM

Latest Trade

59.59USD

Change

-0.07(-0.12%)

Volume

1,036,712

Today's Range

59.55

 - 

59.65

52 Week Range

33.80

 - 

69.43

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
59.66
Open
59.60
Volume
1,036,712
3M AVG Volume
13.65
Today's High
59.65
Today's Low
59.55
52 Week High
69.43
52 Week Low
33.80
Shares Out (MIL)
33.66
Market Cap (MIL)
2,008.18
Forward P/E
27.72
Dividend (Yield %)
--

Next Event

Q3 2019 Cambrex Corp Earnings Release

Latest Developments

More

Cambrex Corp Quarterly Earnings Per Share $0.46

Cambrex To Be Acquired By The Permira Funds For $60.00 Per Share In Cash

Cambrex Doubles cGMP Liquid Filling Capacity At Its Mirabel, Québec Facility

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Industry

Biotechnology & Drugs

Contact Info

1 Meadowlands Plz

+1.201.8043000

https://www.cambrex.com/

Executive Leadership

Shlomo Yanai

Non-Executive Chairman of the Board

Steven Mark Klosk

President, Chief Executive Officer, Director

Gregory P. Sargen

Chief Financial Officer, Executive Vice President, Corporate Development and Strategy

Shawn P. Cavanagh

Chief Operating Officer, Executive Vice President

Dottie Donnelly Brienza

Chief Human Resource Officer, Senior Vice President

Key Stats

2.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.5K

2017

0.5K

2018

0.6K

2019(E)

0.6K
EPS (USD)

2016

2.870

2017

3.170

2018

3.070

2019(E)

2.122
Price To Earnings (TTM)
38.52
Price To Sales (TTM)
3.49
Price To Book (MRQ)
2.97
Price To Cash Flow (TTM)
19.27
Total Debt To Equity (MRQ)
74.97
LT Debt To Equity (MRQ)
73.33
Return on Investment (TTM)
5.02
Return on Equity (TTM)
4.46

Latest News

Permira Funds to buy drug contract manufacturer Cambrex for $2.02 billion

Private equity firm Permira Funds will buy Cambrex Corp <CBM.N> for about $2 billion, the drug contract development and manufacturing company said on Wednesday.

Permira Funds to buy contract manufacturer Cambrex in $2.4 bln deal

Contract development and manufacturing company Cambrex Corp said on Wednesday it was being bought by an affiliate of private equity firm Permira Funds in a deal valued at about $2.4 billion, including net debt.

BRIEF-Cambrex Q1 EPS $0.32 From Continuing Operations

* Q1 EARNINGS PER SHARE $0.32 FROM CONTINUING OPERATIONS EXCLUDING ITEMS

BRIEF-Cambrex Reports Q4 Adj. Earnings Per Share $1.27 From Continuing Operations

* CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Cambrex Announces Investment At Its Charles City, Iowa Plant

* CAMBREX CORP - ANNOUNCED AN INVESTMENT TO EXPAND CHEMICAL AND ANALYTICAL DEVELOPMENT CAPABILITIES AT ITS CHARLES CITY, IOWA PLANT

BRIEF-Cambrex & Astrazeneca Hold Ceremony To Mark Long-Term Supply Agreement At Karlskoga, Sweden Facility

* CAMBREX & ASTRAZENECA HOLD CEREMONY TO MARK LONG-TERM SUPPLY AGREEMENT AT KARLSKOGA, SWEDEN FACILITY Source text for Eikon: Further company coverage:

BRIEF-Cambrex reports Q3 adjusted earnings per share $0.55 from continuing operations

* Q3 adjusted earnings per share $0.55 from continuing operations

BRIEF-Cambrex appoints Gregory Brown to its board of directors

* Gregory B. Brown M.D. Appointed to the board of directors of Cambrex corporation

BRIEF-Cambrex Corp invests $24 mln in a new facility

* To invest $24 million in a new facility to manufacture highly potent APIs at its Charles City, Iowa plant Source text for Eikon: Further company coverage:

BRIEF-Cambrex Corp Q2 revenue $134.6 million

* Q2 adjusted earnings per share $0.76 from continuing operations

BRIEF-Cambrex reports Q3 GAAP earnings per share $0.42 from continuing operations

* Says company expects full year 2016 sales, excluding impact of foreign currency, to increase between 12% and 14% compared to 2015.

BRIEF-Cambrex Corp appoints Bernhard Hampl to the board of directors

* Bernhard Hampl appointed to the board of directors of Cambrex Corporation Source text for Eikon: Further company coverage:

BRIEF-Cambrex to acquire Pharmacore to expand clinical stage API capabilities

* Cambrex to acquire Pharmacore Inc to expand clinical stage API capabilities

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up